SGFEF: Puntuación IA 45/100 — Análisis IA (Abr 2026)
Siegfried Holding AG is a global life sciences company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. They offer contract development and manufacturing services to pharmaceutical companies worldwide.
Datos Clave:
Puntuacion AI: 45/100
Sector: Healthcare
Descripción general de la empresa
Resumen:
Siegfried Holding AG is a global life sciences company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. They offer contract development and manufacturing services to pharmaceutical companies worldwide.
Siegfried Holding AG, a Swiss-based life sciences company with a market cap of $4.38B, specializes in developing and manufacturing APIs and finished dosage forms. With a presence in key global markets, Siegfried offers contract development and manufacturing services, leveraging a 150+ year history and a 12.7% profit margin to serve the pharmaceutical industry.
¿Qué hace SGFEF?
Siegfried Holding AG, founded in 1873 and headquartered in Zofingen, Switzerland, operates within the life sciences sector, focusing on the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company's comprehensive service portfolio includes contract development and manufacturing (CDMO) services, catering to pharmaceutical companies globally. Siegfried's offerings span pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production.
Siegfried manufactures a diverse range of finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products. The company also produces APIs and controlled substances, with a focus on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Additionally, Siegfried licenses oral solid and sterile products, assembles registration dossiers, and offers common technical documents for various products.
Siegfried's long history in the pharmaceutical industry has allowed it to establish a strong reputation for quality and reliability. The company serves a global clientele, providing essential services and products to support the development and manufacturing of pharmaceuticals. With a workforce of 3,886 employees, Siegfried continues to expand its capabilities and geographic reach to meet the evolving needs of the pharmaceutical market.
¿Cuál es la tesis de inversión de SGFEF?
Siegfried Holding AG presents a compelling investment case based on its established position in the CDMO market and its focus on specialized APIs and finished dosage forms. The company's consistent profitability, with a 12.7% profit margin, and a stable dividend yield of 0.49% indicate financial health. Growth catalysts include expanding CDMO contracts and increasing demand for sterile injectables and specialized APIs. Key value drivers are the company's ability to maintain high-quality standards, its strategic partnerships, and its investments in new technologies. Potential risks include regulatory changes in the pharmaceutical industry and competition from larger CDMOs. The company's beta of 0.74 suggests lower volatility compared to the overall market.
¿En qué industria opera SGFEF?
Siegfried Holding AG operates in the specialty and generic drug manufacturing industry, a sector characterized by increasing demand for outsourced pharmaceutical development and manufacturing services. The global CDMO market is expected to continue growing, driven by factors such as the rising cost of drug development, the increasing complexity of pharmaceutical products, and the growing focus on personalized medicine. Siegfried competes with other CDMOs, including CZMWF (Croma-Pharma GmbH), CZMWY (Croma-Pharma GmbH), DNPUF (DNP Corporation), HKMPF (Hoya Corporation), and HKMPY (Hoya Corporation), as well as larger pharmaceutical companies with in-house manufacturing capabilities.
Drug Manufacturers - Specialty & Generic
Healthcare
¿Cuáles son las oportunidades de crecimiento de SGFEF?
- Expansion of CDMO Services: Siegfried can capitalize on the growing demand for outsourced pharmaceutical development and manufacturing services. The global CDMO market is projected to reach $225.2 billion by 2028, growing at a CAGR of 6.9% from 2021. By expanding its capacity and capabilities in areas such as sterile injectables and complex APIs, Siegfried can attract new clients and increase its market share. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Siegfried can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other pharmaceutical companies or acquiring specialized CDMOs can provide access to new markets and expertise. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation and growth. Timeline: Ongoing.
- Focus on Specialized APIs: Siegfried can focus on developing and manufacturing specialized APIs, particularly those used in anesthetics, pain treatment, and central nervous system disorders. These APIs often have higher margins and less competition compared to generic APIs. The global market for APIs is expected to reach $273.4 billion by 2027, growing at a CAGR of 6.1% from 2020. Timeline: Ongoing.
- Investment in Sterile Injectables: Siegfried can invest in expanding its sterile injectable manufacturing capabilities to meet the growing demand for these products. The global market for sterile injectables is projected to reach $738.9 billion by 2027, growing at a CAGR of 9.8% from 2020. This growth is driven by the increasing prevalence of chronic diseases and the development of new biologic drugs that require sterile administration. Timeline: Ongoing.
- Geographic Expansion: Siegfried can expand its geographic presence by establishing new manufacturing facilities or acquiring existing facilities in key markets such as Asia and North America. This would allow the company to better serve its global clients and reduce its reliance on its existing manufacturing sites. The pharmaceutical market in Asia is growing rapidly, driven by increasing healthcare spending and a growing aging population. Timeline: Ongoing.
- Market capitalization of $4.38 billion indicates a significant presence in the specialty and generic drug manufacturing industry.
- P/E ratio of 20.31 suggests a reasonable valuation compared to earnings, reflecting investor confidence in future growth.
- Profit margin of 12.7% demonstrates efficient operations and strong pricing power within its market segments.
- Gross margin of 26.7% indicates the company's ability to manage production costs effectively.
- Dividend yield of 0.49% provides a modest income stream for investors, reflecting a commitment to shareholder returns.
¿Qué productos y servicios ofrece SGFEF?
- Develops and produces active pharmaceutical ingredients (APIs).
- Manufactures pharmaceutical intermediates.
- Produces finished dosage forms, including solid oral dosages.
- Offers sterile and aseptic filling for injectables.
- Manufactures ophthalmics and inhalative products.
- Provides contract development and manufacturing services (CDMO).
- Licenses oral solid and sterile products.
- Assembles registration dossiers for pharmaceutical products.
¿Cómo gana dinero SGFEF?
- Contract development and manufacturing (CDMO) services for pharmaceutical companies.
- Development and manufacturing of active pharmaceutical ingredients (APIs).
- Production of finished dosage forms, including oral solids and sterile injectables.
- Licensing of pharmaceutical products and technologies.
- Pharmaceutical companies seeking outsourced development and manufacturing services.
- Generic drug manufacturers requiring APIs and intermediates.
- Biopharmaceutical companies needing sterile filling and finishing services.
- Companies licensing pharmaceutical products and technologies.
- Specialized Expertise: Siegfried possesses specialized expertise in the development and manufacturing of complex APIs and finished dosage forms, which creates a barrier to entry for new competitors.
- Long-Standing Relationships: The company has established long-standing relationships with its clients, providing a stable source of revenue and repeat business.
- Regulatory Compliance: Siegfried maintains high standards of regulatory compliance, which is essential for operating in the pharmaceutical industry.
- Manufacturing Capabilities: The company has invested in advanced manufacturing facilities and technologies, which allows it to produce high-quality products efficiently.
¿Qué podría impulsar al alza las acciones de SGFEF?
- Ongoing: Expansion of CDMO contracts with pharmaceutical companies.
- Ongoing: Increasing demand for sterile injectables and specialized APIs.
- Ongoing: Strategic partnerships and acquisitions to expand capabilities.
- Ongoing: Investment in new technologies and manufacturing facilities.
- Ongoing: Geographic expansion into emerging markets.
¿Cuáles son los riesgos clave de SGFEF?
- Potential: Regulatory changes in the pharmaceutical industry.
- Potential: Increased competition from larger CDMOs.
- Potential: Pricing pressures from generic drug manufacturers.
- Potential: Patent expirations and loss of exclusivity.
- Ongoing: Limited liquidity due to OTC market trading.
¿Cuáles son las fortalezas clave de SGFEF?
- Strong expertise in API and finished dosage form development and manufacturing.
- Established relationships with pharmaceutical clients.
- Diverse product portfolio.
- Global manufacturing network.
¿Cuáles son las debilidades de SGFEF?
- Reliance on a limited number of key clients.
- Exposure to regulatory changes and compliance risks.
- Competition from larger CDMOs.
- OTC market trading may limit liquidity.
¿Qué oportunidades tiene SGFEF?
- Expanding CDMO services to meet growing demand.
- Strategic partnerships and acquisitions to expand capabilities.
- Focusing on specialized APIs and niche markets.
- Geographic expansion into emerging markets.
¿A qué amenazas se enfrenta SGFEF?
- Increased competition from other CDMOs.
- Pricing pressures from generic drug manufacturers.
- Patent expirations and loss of exclusivity.
- Economic downturns affecting pharmaceutical spending.
¿Quiénes son los competidores de SGFEF?
- Croma-Pharma GmbH — Focuses on aesthetic medicine and hyaluronic acid products. — (CZMWF)
- Croma-Pharma GmbH — Competes in the aesthetics market with a range of dermal fillers. — (CZMWY)
- DNP Corporation — Diversified company with interests in packaging, electronics, and imaging. — (DNPUF)
- Hoya Corporation — Specializes in optical products, including lenses and healthcare products. — (HKMPF)
- Hoya Corporation — Offers a range of healthcare solutions, including medical devices. — (HKMPY)
Key Metrics
- MoonshotScore: 45/100
Company Profile
- CEO: Marcel Imwinkelried
- Headquarters: Zofingen, CH
- Employees: 3,886
- Founded: 2014
AI Insight
AI analysis pending for SGFEF
- OTC Tier: OTC Other
- Disclosure Status: Unknown
Preguntas y respuestas
What does Siegfried Holding AG do?
Siegfried Holding AG is a global life sciences company that specializes in contract development and manufacturing (CDMO) services for the pharmaceutical industry. The company develops and manufactures active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, including solid oral dosages and sterile injectables. Siegfried also offers services such as pharmaceutical and analytical development, process transfer, and commercial manufacturing. The company serves a wide range of pharmaceutical clients, providing essential services and products to support the development and manufacturing of pharmaceuticals.
What do analysts say about SGFEF stock?
Analyst sentiment on SGFEF is not available from the provided data. However, key valuation metrics include a P/E ratio of 20.31 and a dividend yield of 0.49%. Growth considerations would likely focus on the company's ability to expand its CDMO services, develop specialized APIs, and capitalize on the growing demand for sterile injectables. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for SGFEF?
The main risks for Siegfried Holding AG include regulatory changes in the pharmaceutical industry, increased competition from larger CDMOs, and pricing pressures from generic drug manufacturers. Patent expirations and loss of exclusivity can also impact the company's revenue. Additionally, as an OTC-listed stock, SGFEF faces risks related to limited liquidity and regulatory oversight. Investors should carefully consider these risks before investing in SGFEF.